,address1,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,19805 North Creek Parkway,Bothell,WA,98011,United States,305 425 1780,https://www.cocrystalpharma.com,Biotechnology,Healthcare,"Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.",12,"{'maxAge': 1, 'name': 'Dr. Roger D. Kornberg Ph.D.', 'age': 75, 'title': 'Co-Founder, Chairman, Chief Scientist & Chairman of Scientific Advisory Board', 'yearBorn': 1947, 'fiscalYear': 2022, 'totalPay': 125000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.04,2.03,1.9501,2.1,2.04,2.03,1.9501,2.1,0.0,1.199515,-0.8684211,33219,33219,31706,57530,57530,1.99,2.04,800,1100,20144124,1.74,4.32,2.6198,2.41255,0.0,0.0,USD,-12098896,0.0,7113412,10173800,14575,30836,1690761600,1693440000,0.0014,0.30025998,0.07263,0.42,0.0019,3.409,0.5808155,1672444800,1703980800,1688083200,-19556000,-2.31,-2.28,1:30,1516752000,0.622,NCM,EQUITY,COCP,COCP,"Cocrystal Pharma, Inc.","Cocrystal Pharma, Inc.",1329921000,America/New_York,EDT,-14400000,1.98,12.0,7.0,9.67,10.0,2.0,buy,3,32419000,3.187,-19455000,176000,21.188,22.534,0.507,-0.27698,-0.4652,-15094375,-22460000,0.0,0.0,0.0,USD,
1,19805 North Creek Parkway,Bothell,WA,98011,United States,305 425 1780,https://www.cocrystalpharma.com,Biotechnology,Healthcare,"Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.",12,"{'maxAge': 1, 'name': 'Dr. Sam  Lee Ph.D.', 'age': 62, 'title': 'Co-Founder, Co-CEO & Pres', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 521384, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.04,2.03,1.9501,2.1,2.04,2.03,1.9501,2.1,0.0,1.199515,-0.8684211,33219,33219,31706,57530,57530,1.99,2.04,800,1100,20144124,1.74,4.32,2.6198,2.41255,0.0,0.0,USD,-12098896,0.0,7113412,10173800,14575,30836,1690761600,1693440000,0.0014,0.30025998,0.07263,0.42,0.0019,3.409,0.5808155,1672444800,1703980800,1688083200,-19556000,-2.31,-2.28,1:30,1516752000,0.622,NCM,EQUITY,COCP,COCP,"Cocrystal Pharma, Inc.","Cocrystal Pharma, Inc.",1329921000,America/New_York,EDT,-14400000,1.98,12.0,7.0,9.67,10.0,2.0,buy,3,32419000,3.187,-19455000,176000,21.188,22.534,0.507,-0.27698,-0.4652,-15094375,-22460000,0.0,0.0,0.0,USD,
2,19805 North Creek Parkway,Bothell,WA,98011,United States,305 425 1780,https://www.cocrystalpharma.com,Biotechnology,Healthcare,"Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.",12,"{'maxAge': 1, 'name': 'Mr. James J. Martin CPA, CPA, M.B.A., MBA', 'age': 55, 'title': 'Co-CEO, CFO & Corp. Sec.', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 521384, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.04,2.03,1.9501,2.1,2.04,2.03,1.9501,2.1,0.0,1.199515,-0.8684211,33219,33219,31706,57530,57530,1.99,2.04,800,1100,20144124,1.74,4.32,2.6198,2.41255,0.0,0.0,USD,-12098896,0.0,7113412,10173800,14575,30836,1690761600,1693440000,0.0014,0.30025998,0.07263,0.42,0.0019,3.409,0.5808155,1672444800,1703980800,1688083200,-19556000,-2.31,-2.28,1:30,1516752000,0.622,NCM,EQUITY,COCP,COCP,"Cocrystal Pharma, Inc.","Cocrystal Pharma, Inc.",1329921000,America/New_York,EDT,-14400000,1.98,12.0,7.0,9.67,10.0,2.0,buy,3,32419000,3.187,-19455000,176000,21.188,22.534,0.507,-0.27698,-0.4652,-15094375,-22460000,0.0,0.0,0.0,USD,
